Sandoz and Pear Therapeutics have this week launched reSET-O in the US to help treat opioid use disorder (OUD) after the treatment was cleared by the FDA in December.
The reSET-O prescription digital therapeutic (PDT) is a 12-week cognitive behavioural therapy intended to be used in addition to outpatient treatment.
It includes transmucosal buprenorphine, a commonly used medication to treat opioid addiction, and contingency management designed to provide incentives to reinforce positive behaviours.
reSET-O is available by prescription only for patients 18 years or older under the care of a clinician.
“The launch of reSET-O provides an important technology-based treatment option for patients with Opioid Use Disorder and may fundamentally change how they interact with their therapies,” said Richard Francis, CEO of Sandoz (a division of Novartis).
Corey McCann, President and CEO of Pear Therapeutics, added: “We believe prescription digital therapeutics can transform the way clinicians treat addiction by providing a way for patients to access treatment when and where it’s needed.
“reSET-O has been clinically proven to increase the likelihood that a patient will remain in treatment, while also providing a way for patients to access treatment anytime, anywhere, under clinician supervision.”
Under the terms of a commercial deal announced in April 2018, Sandoz will lead marketing and commercialisation of reSET-O and reSET, Pear’s prescription digital therapeutics for the treatment of Substance Use Disorder and Opioid Use Disorder, respectively.
Sandoz launched reSET in November 2018 and now has made reSET-O available to patients in the US.